pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 45 Non-oncology: 29
Oncology: 16
Under Consideration for Negotiation 17 Non-oncology: 11
Oncology: 6
Completed Negotiations 722 With Letter of Intent: 621
Without agreement: 101
Negotiations That Were Not Pursued 108

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Imbruvica Janssen Inc. Chronic lymphocytic leukemia (CLL), in adult patients with previously untreated CLL, including those with 17p deletion
Tyenne Fresenius Kabi Canada Ltd. Multiple Indications
Imbruvica Janssen Inc. Waldenström's Macroglobulinemia
Bimzelx UCB Canada Inc. Ankylosing spondylitis
Bimzelx UCB Canada Inc. Psoriatic Arthritis
Awiqli Novo Nordisk Canada Inc. Diabetes Mellitus, Type 2

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Qulipta AbbVie Corporation Migraine, prevention
Orladeyo BioCryst Pharmaceuticals Inc. Hereditary Angioedema
Slynd Duchesnay Inc. Contraceptive, oral

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
Doptelet Sobi Canada Inc. Chronic Immune Thrombocytopenia
Sogroya Novo Nordisk Canada Inc. Growth hormone deficiency
Rybrevant Janssen Inc. Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, in adult patients with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy